First half of 2014: broadened clinical portfolio and strengthened cash position

• Acquisition in February 2014 of IPH2201, anti-NKG2A antibody, a Phase II-ready first-in-class checkpoint inhibitor

• Successful €50m capital increase subscribed by specialized investors

• Cash and cash equivalents amounting to €78.9 million

• All programs on track

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, reports today its consolidated financial results for the first half of 2014.

Hervé Brailly, Chief Executive Officer of Innate Pharma, commented: “This first half of 2014 has been marked by the acquisition of a novel clinical-stage checkpoint inhibitor. The Company has secured the financial resources for its Phase II development, with a successful €50m fund raising subscribed by specialized investors. Our cash horizon thus remains end of 2017, by which time we expect to create significant value from our assets.

Lirilumab, licensed to Bristol-Myers Squibb, should deliver major data in 2015. We expect to have the results of the randomized Phase II trial with lirilumab as single-agent in Acute Myeloid Leukemia end of 2015. Recruitment for this trial was completed last July.

We expect to enroll a first patient in the first Phase II trial with IPH2201 by the end of 2014, and initiate other trials in the first half of 2015.

Recently, IPH4102 was granted orphan drug status in the EU; it is on track to become our third first-in-class candidate in clinical development in 2015.

Innate Pharma enters an exciting stage in its development, with a significant expansion of its clinical-stage portfolio, comforting its unique positioning in the very promising area of immuno-oncology.”

A meeting for fund managers, financial analysts and journalists will be held today at 11:30 am (CET) at the SFAF premises in Paris

24, rue de Penthièvre, 75008

A conference call will be held today at 2:00pm (CET)

Dial in number: +33 (0)1 70 77 09 40

A replay will be available during three months after the conference call

Dial in number: +33 (0)1 72 00 15 00 - Access number: 289032#